Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Neoplasms 2Carcinoma, Ovarian Epithelial 2Uveal Melanoma 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Multiple Myeloma 1Melanoma 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia 1Hemangiosarcoma 1Esophagogastric Cancer 1Esophageal Neoplasms 1Disorders of Sex Development 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1Pemetrexed 1Oxaliplatin 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophagogastric Cancer × STA 9090 × Clear all
NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Massachusetts General Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡